Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal DiseaseGlobeNewsWire • 03/24/20
Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 12/09/19
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific MeetingGlobeNewsWire • 10/28/19
Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses24/7 Wall Street • 08/26/19